Seibert Volker, Ebert Matthias P A, Buschmann Thomas
EUROPROTEOME AG, Neuendorfstrasse 24b, D-16761 Hennigsdorf, Germany.
Brief Funct Genomic Proteomic. 2005 May;4(1):16-26. doi: 10.1093/bfgp/4.1.16.
For most cancers, survival rates depend on the early detection of the disease. So far, no biomarkers exist to cope with this difficult task. New proteomic technologies have brought the hope of discovering novel early cancer-specific biomarkers in complex biological samples and/or of the setting up of new clinically relevant test systems. Novel mass spectrometry-(MS) based technologies in particular, such as surface-enhanced laser desorption/ionisation time of flight (SELDI-ToF-MS), have shown promising results in the recent literature. Here, proteomic profiles of control and disease states are compared to find biomarkers for diagnosis. This paper aims to address the authors' own work and that of other groups in clinical cancer proteomics based on SELDI-ToF-MS. Shortcomings and hopes for the future are discussed.
对于大多数癌症来说，生存率取决于疾病的早期检测。到目前为止，还没有生物标志物能够应对这项艰巨任务。新的蛋白质组学技术带来了在复杂生物样本中发现新型早期癌症特异性生物标志物和/或建立新的临床相关检测系统的希望。特别是基于新型质谱（MS）的技术，如表面增强激光解吸/电离飞行时间质谱（SELDI-ToF-MS），在最近的文献中已显示出有前景的结果。在这里，通过比较对照和疾病状态的蛋白质组图谱来寻找诊断生物标志物。本文旨在阐述作者自己以及其他团队基于SELDI-ToF-MS在临床癌症蛋白质组学方面的工作。文中还讨论了不足之处和对未来的期望。
